Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company, has reported significant progress in its Phase 3 program for HLP003, its lead investigational therapy for major depressive disorder (MDD). The company announced the completion of enrollment in APPROACH, the first pivotal study, with topline data expected in the fourth quarter of 2026. This milestone brings the company closer to a potential new treatment option for the millions of patients who do not adequately respond to existing antidepressants.
The APPROACH study is part of the PARADIGM program, which also includes the EMBRACE trial, currently enrolling participants, and the EXTEND long-term safety study. The rapid advancement of these trials underscores the company's commitment to addressing the significant unmet need in MDD, a condition that affects over 21 million adults in the United States alone. HLP003 has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration, highlighting its potential to offer a meaningful improvement over current therapies.
In addition to the HLP003 program, Helus Pharma is advancing HLP004 for generalized anxiety disorder (GAD). Phase 2 results demonstrated a statistically significant and clinically meaningful improvement from baseline, and the company expects to finalize the design of the next study by the end of the third quarter. This pipeline breadth positions Helus Pharma to potentially address multiple mental health conditions with its novel serotonergic agonists (NSAs).
Financially, the company reported cash of $166.4 million as of June 30, 2026, which it believes is sufficient to fund operations into the second half of 2027. The quarterly net loss was $47.8 million, compared to $24.6 million in the same period last year, reflecting increased investment in the Phase 3 trials. Cash-based operating expenses rose to $37.5 million from $23.9 million, driven by the expansion of the clinical programs.
The importance of these developments cannot be overstated. Major depressive disorder is a leading cause of disability worldwide, and current treatments often take weeks to show effect and are ineffective for many patients. HLP003, if approved, could offer a faster-acting and more durable response, potentially transforming the treatment landscape. The completion of enrollment in the first pivotal study is a critical step toward bringing this therapy to patients.
Furthermore, the progress with HLP004 in GAD expands the company's potential market. GAD affects nearly 7 million U.S. adults, and current therapies also have limitations. By advancing both programs, Helus Pharma is building a robust pipeline that could address multiple mental health conditions with a single platform.
Investors and stakeholders are watching closely as the company moves toward key data readouts. The topline results from APPROACH in Q4 2026 will be a major catalyst, potentially validating the efficacy and safety of HLP003. If successful, Helus Pharma could become a leader in the emerging field of psychedelic-inspired therapies for mental health.
For more information on the company's progress and pipeline, visit the press release at https://ibn.fm/yfpOW.
